Recent malaria does not substantially impact COVID-19 antibody response or rates of symptomatic illness in communities with high malaria and COVID-19 transmission in Mali, West Africa
John Woodford(National Institute of Allergy and Infectious Diseases), Patrick E. Duffy(National Institute of Allergy and Infectious Diseases), Ibrahim H. Soumbounou, Halimatou Diawara(Université des Sciences, des Techniques et des Technologies de Bamako), Issaka Sagara, Kourane Sissoko(Université des Sciences, des Techniques et des Technologies de Bamako), Santara Gaoussou(University of Bamako), Djibrilla Issiaka, Bayaya Haidara(Université des Sciences, des Techniques et des Technologies de Bamako), Irfan Zaidi(National Institutes of Health), Seydou Sankare(Université des Sciences, des Techniques et des Technologies de Bamako), Seydou Traoré, Justin Doritchamou(National Institutes of Health), Oumar Attaher(University of Bamako), Oumar M Dicko(Université des Sciences, des Techniques et des Technologies de Bamako), Sadio dite Koni Diarra(Université des Sciences, des Techniques et des Technologies de Bamako), Abdoulaye Katilé(Université des Sciences, des Techniques et des Technologies de Bamako), Sidi M. Niambele, Alassane Dicko(University of Bamako), Mahamadoun H. Assadou(Université des Sciences, des Techniques et des Technologies de Bamako), Almahamoudou Mahamar, Bourama Kamaté(Université des Sciences, des Techniques et des Technologies de Bamako), Moussa Traoré(Université des Sciences, des Techniques et des Technologies de Bamako), Amatigué Zéguimé
Cited by 7
Related Papers
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial
|The Lancet|2024|345
Intermittent Treatment to Prevent Pregnancy Malaria Does Not Confer Benefit in an Area of Widespread Drug Resistance
|Clinical Infectious Diseases|2011|154